Literature DB >> 9498471

Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies.

S Conti1, F Fanti, W Magliani, M Gerloni, D Bertolotti, A Salati, A Cassone, L Polonelli.   

Abstract

Human natural (KTAb), murine monoclonal (KTMAb), and single-chain recombinant (KTScFv) candidacidal antibodies representing the internal image of a killer toxin from the yeast Pichia anomala (KT), characterized by a wide spectrum of antibiotic activity, exerted a lethal effect against a KT-sensitive multidrug-resistant isolate of Mycobacterium tuberculosis. KTMAb and KTScFv were produced by the hybridoma and DNA technologies, respectively, from the spleen lymphocytes of animals immunized with the idiotype of a KT-neutralizing MAb (MAb KT4), while KTAb were purified against MAb KT4 from the vaginal fluid of women infected with Candida albicans cells bearing an idiotype-like KT cell wall receptor. Mycobactericidal activity was related to the binding of KTAb, KTMAb, and KTScFv to the cell surface of KT-sensitive bacterial cells and was prevented by specific absorption of KT-like antibodies onto MAb KT4. These data identify a novel potentially useful immunotherapeutic approach to tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9498471     DOI: 10.1086/517815

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Do CD1-restricted T cells contribute to antibody-mediated immunity against Mycobacterium tuberculosis?

Authors:  Mark L Lang; Aharona Glatman-Freedman
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

2.  Production of an engineered killer peptide in Nicotiana benthamiana by using a potato virus X expression system.

Authors:  Marcello Donini; Chiara Lico; Selene Baschieri; Stefania Conti; Walter Magliani; Luciano Polonelli; Eugenio Benvenuto
Journal:  Appl Environ Microbiol       Date:  2005-10       Impact factor: 4.792

Review 3.  B cells and antibodies in the defense against Mycobacterium tuberculosis infection.

Authors:  Jacqueline M Achkar; John Chan; Arturo Casadevall
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

4.  Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation.

Authors:  Elio Cenci; Antonella Mencacci; Antonio Spreca; Claudia Montagnoli; Angela Bacci; Katia Perruccio; Andrea Velardi; Walter Magliani; Stefania Conti; Luciano Polonelli; Luigina Romani
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 5.  Antibody-mediated immunity against tuberculosis: implications for vaccine development.

Authors:  Jacqueline M Achkar; Arturo Casadevall
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

6.  A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities.

Authors:  María D Moragues; Miren J Omaetxebarria; Natalia Elguezabal; María J Sevilla; Stefania Conti; Luciano Polonelli; José Pontón
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

7.  Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis.

Authors:  Luciano Polonelli; Walter Magliani; Stefania Conti; Luisa Bracci; Luisa Lozzi; Paolo Neri; Daniela Adriani; Flavia De Bernardis; Antonio Cassone
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

Review 8.  Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis.

Authors:  Jacqueline M Achkar; John Chan; Arturo Casadevall
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-09       Impact factor: 6.915

Review 9.  Antibodies and tuberculosis.

Authors:  Ashley J Jacobs; Juthathip Mongkolsapaya; Gavin R Screaton; Helen McShane; Robert J Wilkinson
Journal:  Tuberculosis (Edinb)       Date:  2016-08-26       Impact factor: 3.131

10.  Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities.

Authors:  Luciano Polonelli; José Pontón; Natalia Elguezabal; María Dolores Moragues; Claudio Casoli; Elisabetta Pilotti; Paola Ronzi; Andrey S Dobroff; Elaine G Rodrigues; Maria A Juliano; Domenico Leonardo Maffei; Walter Magliani; Stefania Conti; Luiz R Travassos
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.